ReShape Lifesciences Inc.

RSLS

US76090R2004

Advanced Medical Equipment & Technology

Delayed Nasdaq Other stock markets 10:11:31 07/06/2024 pm IST			5-day change	1st Jan Change
0.2252 ^USD	-3.84%		-11.65%	-9.81%

15/05	ReShape Lifesciences Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
15/05	Transcript : ReShape Lifesciences Inc., Q1 2024 Earnings Call, May 15, 2024

Obalon Therapeutics, Inc. has Changed its Name to ReShape Lifesciences Inc

June 16, 2021 at 02:42 am IST

Obalon Therapeutics, Inc. changed its name to ReShape Lifesciences Inc.

Latest news about ReShape Lifesciences Inc.

ReShape Lifesciences Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	16/05	CI
Transcript : ReShape Lifesciences Inc., Q1 2024 Earnings Call, May 15, 2024	16/05
Earnings Flash (RSLS) RESHAPE LIFESCIENCES Posts Q1 Revenue $1.9M, vs. Street Est of $2.1M	16/05	MT
North American Morning Briefing : Big Banks Kick -2-	12/04	DJ
Transcript : ReShape Lifesciences Inc., Q4 2023 Earnings Call, Apr 01, 2024	02/04
ReShape Lifesciences Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	02/04	CI
Certain Restricted Stock Units of ReShape Lifesciences Inc. are subject to a Lock-Up Agreement Ending on 30-MAR-2024.	30/03	CI
Certain Warrants of ReShape Lifesciences Inc. are subject to a Lock-Up Agreement Ending on 30-MAR-2024.	30/03	CI
Certain Options of ReShape Lifesciences Inc. are subject to a Lock-Up Agreement Ending on 30-MAR-2024.	30/03	CI
Certain Common Stock of ReShape Lifesciences Inc. are subject to a Lock-Up Agreement Ending on 30-MAR-2024.	30/03	CI
ReShape Lifesciences Gets US Patent for Intragastric Balloon Weight-Loss System	28/03	MT
ReShape Lifesciences Receives Notice of Allowance for Additional U.S. Patent Related to Intragastric Balloon System	28/03	CI
Reshape Lifesciences® Announces First Surgeries Utilizing Next-Generation Lap-Band 2.0 Flex	22/02	CI
Top Midday Gainers	14/12	MT
North American Morning Briefing : Traders Await FOMC, Powell	13/12	DJ
ReShape Lifesciences®? Receives FDA PMA Supplement Approval for Its Next-Generation Lap-Band®? 2.0 FLEX	13/12	CI
ReShape Lifesciences Gets FDA Approval for PMA Supplement Used in Latest Lap-Band	13/12	DJ
ReShape Lifesciences Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	09/11	CI
ReShape Lifesciences Inc. Reports Impairment of Long-Lived Assets for the Third Quarter Ended September 30, 2023	09/11	CI
Transcript : ReShape Lifesciences Inc., Q3 2023 Earnings Call, Nov 08, 2023	09/11
Earnings Flash (RSLS) RESHAPE LIFESCIENCES Posts Q3 Revenue $2.2M, vs. Street Est of $2.4M	09/11	MT
Sector Update: Health Care Stocks Lower Late Afternoon	30/23/30	MT
Sector Update: Health Care Stocks Declining Friday Afternoon	29/23/29	MT
ReShape Lifesciences Prices $3 Million Offering at $0.33 Per Unit	29/23/29	MT
ReShape Lifesciences Inc. Signs Exclusive License Agreement With Biorad Medisys for Obalon(R) Gastric Balloon System	21/23/21	CI

Chart ReShape Lifesciences Inc.

Duration

Period

More charts

ReShape Lifesciences Inc. is a weight-loss and metabolic health-solutions company. The Company offers an integrated portfolio of products and services that manage and treat obesity and metabolic disease. Its Lap-Band System provides minimally invasive, long-term treatment of obesity and is an alternative to more invasive surgical stapling procedures, such as gastric bypass or sleeve gastrectomy. The investigational Diabetes Bloc-Stim Neuromodulation (DBSN) system utilizes a vagus nerve block and stimulation technology platform for the treatment of type II diabetes and metabolic disorders. The Obalon balloon technology is a non-surgical, swallowable, gas-filled intra-gastric balloon that is designed to provide long-lasting weight loss. Its ReShape Calibration tubes are multifunctional devices compared to reusable bougies and disposable gastric tubes. Its Lap-Band 2.0, like the original Lap-Band System, is designed to provide minimally invasive long-term treatment of severe obesity.

Sector

Advanced Medical Equipment & Technology

Calendar

12/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for ReShape Lifesciences Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.2342 USD

Average target price

1 USD

Spread / Average Target

+326.99%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Advanced Medical Equipment & Technology

	1st Jan change	Capi.
RESHAPE LIFESCIENCES INC.	-9.81%	5.49M
THERMO FISHER SCIENTIFIC	+9.91%	221B
DANAHER CORPORATION	+14.81%	198B
INTUITIVE SURGICAL, INC.	+24.44%	148B
BOSTON SCIENTIFIC CORPORATION	+33.75%	112B
SIEMENS HEALTHINEERS AG	+4.75%	66.85B
EDWARDS LIFESCIENCES CORPORATION	+15.25%	52.84B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	+3.16%	50.86B
AGILENT TECHNOLOGIES, INC.	-4.78%	38.75B
GE HEALTHCARE TECHNOLOGIES INC.	-0.54%	35.15B

Other Advanced Medical Equipment & Technology

ReShape Lifesciences Inc.

Equities

RSLS

US76090R2004

Advanced Medical Equipment & Technology

Obalon Therapeutics, Inc. has Changed its Name to ReShape Lifesciences Inc

Latest news about ReShape Lifesciences Inc.

Chart ReShape Lifesciences Inc.

Company Profile

Income Statement Evolution

Ratings for ReShape Lifesciences Inc.

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Advanced Medical Equipment & Technology